Novel active agents in patients with advanced NSCLC without driver mutations who have progressed after first-line chemotherapy

Christian Manegold, Alex Adjei, Federico Bussolino, Federico Cappuzzo, Lucio Crino, Rafal Dziadziuszko, David S Ettinger, Dean Fennell, Keith Kerr, Thierry Le Chevalier, Natasha Leighl, Mauro Papotti, Luis Paz-Ares, Maurice Pérol, Solange Peters, Robert Pirker, Elisabeth Quoix, Martin Reck, Egbert Smit, Everett Vokes & 2 others Nico Van Zandwijk, Caicun Zhou

Research output: Contribution to journalReview article

Abstract

Despite the efficacy of a number of first-line treatments, most patients with advanced-stage non-small cell lung cancer (NSCLC) experience disease progression that warrants further treatment. In this review, we examine the role of novel active agents for patients who progress after first-line therapy and who are not candidates for targeted therapies. More therapeutic options are needed for the management of patients with NSCLC after failure of first-line chemotherapy. A PubMed search was performed for articles from January 2012 to May 2015 using the keywords NSCLC, antiangiogenic, immunotherapy, second-line, novel therapies and English language articles only. Relevant papers were reviewed; papers outside that period were considered on a case-by-case basis. A search of oncology congresses was performed to identify relevant abstracts over this period. In recent years, antiangiogenic agents and immune checkpoint inhibitors have been added to our armamentarium to treat patients with advanced NSCLC who have progressed on first-line chemotherapy. These include nintedanib, a triple angiokinase inhibitor; ramucirumab, a vascular endothelial growth factor receptor-2 antibody; and nivolumab, pembrolizumab and atezolizumab, just three of a growing list of antibodies targeting the programmed death receptor-1 (PD-1)/PD ligand-1 pathway. Predictive and prognostic factors in NSCLC treatment will help to optimise treatment with these novel agents. The approval of new treatments for patients with NSCLC after the failure of first-line chemotherapy has increased options after a decade of few advances, and holds promise for future evolution of the management of NSCLC.

Original languageEnglish (US)
Article numbere000118
JournalESMO Open
Volume1
Issue number6
DOIs
StatePublished - Dec 1 2016

Fingerprint

Proxy
Non-Small Cell Lung Carcinoma
Drug Therapy
Mutation
Therapeutics
Language Therapy
Vascular Endothelial Growth Factor Receptor-2
Death Domain Receptors
Angiogenesis Inhibitors
Antibodies
PubMed
Immunotherapy
Disease Progression
Ligands

Keywords

  • Antiangiogenesis
  • Immune checkpoint inhibitors
  • Nintedanib
  • Prognostic factors
  • Ramucirumab

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Manegold, C., Adjei, A., Bussolino, F., Cappuzzo, F., Crino, L., Dziadziuszko, R., ... Zhou, C. (2016). Novel active agents in patients with advanced NSCLC without driver mutations who have progressed after first-line chemotherapy. ESMO Open, 1(6), [e000118]. https://doi.org/10.1136/esmoopen-2016-000118

Novel active agents in patients with advanced NSCLC without driver mutations who have progressed after first-line chemotherapy. / Manegold, Christian; Adjei, Alex; Bussolino, Federico; Cappuzzo, Federico; Crino, Lucio; Dziadziuszko, Rafal; Ettinger, David S; Fennell, Dean; Kerr, Keith; Le Chevalier, Thierry; Leighl, Natasha; Papotti, Mauro; Paz-Ares, Luis; Pérol, Maurice; Peters, Solange; Pirker, Robert; Quoix, Elisabeth; Reck, Martin; Smit, Egbert; Vokes, Everett; Van Zandwijk, Nico; Zhou, Caicun.

In: ESMO Open, Vol. 1, No. 6, e000118, 01.12.2016.

Research output: Contribution to journalReview article

Manegold, C, Adjei, A, Bussolino, F, Cappuzzo, F, Crino, L, Dziadziuszko, R, Ettinger, DS, Fennell, D, Kerr, K, Le Chevalier, T, Leighl, N, Papotti, M, Paz-Ares, L, Pérol, M, Peters, S, Pirker, R, Quoix, E, Reck, M, Smit, E, Vokes, E, Van Zandwijk, N & Zhou, C 2016, 'Novel active agents in patients with advanced NSCLC without driver mutations who have progressed after first-line chemotherapy', ESMO Open, vol. 1, no. 6, e000118. https://doi.org/10.1136/esmoopen-2016-000118
Manegold, Christian ; Adjei, Alex ; Bussolino, Federico ; Cappuzzo, Federico ; Crino, Lucio ; Dziadziuszko, Rafal ; Ettinger, David S ; Fennell, Dean ; Kerr, Keith ; Le Chevalier, Thierry ; Leighl, Natasha ; Papotti, Mauro ; Paz-Ares, Luis ; Pérol, Maurice ; Peters, Solange ; Pirker, Robert ; Quoix, Elisabeth ; Reck, Martin ; Smit, Egbert ; Vokes, Everett ; Van Zandwijk, Nico ; Zhou, Caicun. / Novel active agents in patients with advanced NSCLC without driver mutations who have progressed after first-line chemotherapy. In: ESMO Open. 2016 ; Vol. 1, No. 6.
@article{011dc9deb09b42109dd55f033f4b27d9,
title = "Novel active agents in patients with advanced NSCLC without driver mutations who have progressed after first-line chemotherapy",
abstract = "Despite the efficacy of a number of first-line treatments, most patients with advanced-stage non-small cell lung cancer (NSCLC) experience disease progression that warrants further treatment. In this review, we examine the role of novel active agents for patients who progress after first-line therapy and who are not candidates for targeted therapies. More therapeutic options are needed for the management of patients with NSCLC after failure of first-line chemotherapy. A PubMed search was performed for articles from January 2012 to May 2015 using the keywords NSCLC, antiangiogenic, immunotherapy, second-line, novel therapies and English language articles only. Relevant papers were reviewed; papers outside that period were considered on a case-by-case basis. A search of oncology congresses was performed to identify relevant abstracts over this period. In recent years, antiangiogenic agents and immune checkpoint inhibitors have been added to our armamentarium to treat patients with advanced NSCLC who have progressed on first-line chemotherapy. These include nintedanib, a triple angiokinase inhibitor; ramucirumab, a vascular endothelial growth factor receptor-2 antibody; and nivolumab, pembrolizumab and atezolizumab, just three of a growing list of antibodies targeting the programmed death receptor-1 (PD-1)/PD ligand-1 pathway. Predictive and prognostic factors in NSCLC treatment will help to optimise treatment with these novel agents. The approval of new treatments for patients with NSCLC after the failure of first-line chemotherapy has increased options after a decade of few advances, and holds promise for future evolution of the management of NSCLC.",
keywords = "Antiangiogenesis, Immune checkpoint inhibitors, Nintedanib, Prognostic factors, Ramucirumab",
author = "Christian Manegold and Alex Adjei and Federico Bussolino and Federico Cappuzzo and Lucio Crino and Rafal Dziadziuszko and Ettinger, {David S} and Dean Fennell and Keith Kerr and {Le Chevalier}, Thierry and Natasha Leighl and Mauro Papotti and Luis Paz-Ares and Maurice P{\'e}rol and Solange Peters and Robert Pirker and Elisabeth Quoix and Martin Reck and Egbert Smit and Everett Vokes and {Van Zandwijk}, Nico and Caicun Zhou",
year = "2016",
month = "12",
day = "1",
doi = "10.1136/esmoopen-2016-000118",
language = "English (US)",
volume = "1",
journal = "ESMO Open",
issn = "2059-7029",
publisher = "BMJ Publishing Group",
number = "6",

}

TY - JOUR

T1 - Novel active agents in patients with advanced NSCLC without driver mutations who have progressed after first-line chemotherapy

AU - Manegold, Christian

AU - Adjei, Alex

AU - Bussolino, Federico

AU - Cappuzzo, Federico

AU - Crino, Lucio

AU - Dziadziuszko, Rafal

AU - Ettinger, David S

AU - Fennell, Dean

AU - Kerr, Keith

AU - Le Chevalier, Thierry

AU - Leighl, Natasha

AU - Papotti, Mauro

AU - Paz-Ares, Luis

AU - Pérol, Maurice

AU - Peters, Solange

AU - Pirker, Robert

AU - Quoix, Elisabeth

AU - Reck, Martin

AU - Smit, Egbert

AU - Vokes, Everett

AU - Van Zandwijk, Nico

AU - Zhou, Caicun

PY - 2016/12/1

Y1 - 2016/12/1

N2 - Despite the efficacy of a number of first-line treatments, most patients with advanced-stage non-small cell lung cancer (NSCLC) experience disease progression that warrants further treatment. In this review, we examine the role of novel active agents for patients who progress after first-line therapy and who are not candidates for targeted therapies. More therapeutic options are needed for the management of patients with NSCLC after failure of first-line chemotherapy. A PubMed search was performed for articles from January 2012 to May 2015 using the keywords NSCLC, antiangiogenic, immunotherapy, second-line, novel therapies and English language articles only. Relevant papers were reviewed; papers outside that period were considered on a case-by-case basis. A search of oncology congresses was performed to identify relevant abstracts over this period. In recent years, antiangiogenic agents and immune checkpoint inhibitors have been added to our armamentarium to treat patients with advanced NSCLC who have progressed on first-line chemotherapy. These include nintedanib, a triple angiokinase inhibitor; ramucirumab, a vascular endothelial growth factor receptor-2 antibody; and nivolumab, pembrolizumab and atezolizumab, just three of a growing list of antibodies targeting the programmed death receptor-1 (PD-1)/PD ligand-1 pathway. Predictive and prognostic factors in NSCLC treatment will help to optimise treatment with these novel agents. The approval of new treatments for patients with NSCLC after the failure of first-line chemotherapy has increased options after a decade of few advances, and holds promise for future evolution of the management of NSCLC.

AB - Despite the efficacy of a number of first-line treatments, most patients with advanced-stage non-small cell lung cancer (NSCLC) experience disease progression that warrants further treatment. In this review, we examine the role of novel active agents for patients who progress after first-line therapy and who are not candidates for targeted therapies. More therapeutic options are needed for the management of patients with NSCLC after failure of first-line chemotherapy. A PubMed search was performed for articles from January 2012 to May 2015 using the keywords NSCLC, antiangiogenic, immunotherapy, second-line, novel therapies and English language articles only. Relevant papers were reviewed; papers outside that period were considered on a case-by-case basis. A search of oncology congresses was performed to identify relevant abstracts over this period. In recent years, antiangiogenic agents and immune checkpoint inhibitors have been added to our armamentarium to treat patients with advanced NSCLC who have progressed on first-line chemotherapy. These include nintedanib, a triple angiokinase inhibitor; ramucirumab, a vascular endothelial growth factor receptor-2 antibody; and nivolumab, pembrolizumab and atezolizumab, just three of a growing list of antibodies targeting the programmed death receptor-1 (PD-1)/PD ligand-1 pathway. Predictive and prognostic factors in NSCLC treatment will help to optimise treatment with these novel agents. The approval of new treatments for patients with NSCLC after the failure of first-line chemotherapy has increased options after a decade of few advances, and holds promise for future evolution of the management of NSCLC.

KW - Antiangiogenesis

KW - Immune checkpoint inhibitors

KW - Nintedanib

KW - Prognostic factors

KW - Ramucirumab

UR - http://www.scopus.com/inward/record.url?scp=85052683089&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052683089&partnerID=8YFLogxK

U2 - 10.1136/esmoopen-2016-000118

DO - 10.1136/esmoopen-2016-000118

M3 - Review article

VL - 1

JO - ESMO Open

JF - ESMO Open

SN - 2059-7029

IS - 6

M1 - e000118

ER -